Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials.

Autor: Kiem D; III Medical Department, Paracelsus Medical University, Salzburg, Austria., Ocker M; Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Campus, Charité Mitte, Charité University Medicine Berlin, Berlin, Germany.; EO Translational Insights Consulting GmbH, Berlin, Germany.; Tacalyx GmbH, Berlin, Germany., Greil R; III Medical Department, Paracelsus Medical University, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria., Neureiter D; Cancer Cluster Salzburg, Salzburg, Austria.; Institute of Pathology, Paracelsus Medical University, University Hospital Salzburg (SALK), Salzburg, Austria., Melchardt T; III Medical Department, Paracelsus Medical University, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.

Publikováno v: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2024 Mar; Vol. 33 (3), pp. 229-242. Date of Electronic Publication: 2024 Feb 23.

Clinical features of cervical dystonia patients classified by the COL-CAP concept and treated with ultrasound-guided botulinum neurotoxin.

Autor: Szabó M; Department of Neurology, Szent-Györgyi Albert Clinical Centre, Szent-Györgyi Albert Faculty of Medicine, University of Szeged, Szeged., DO Kiem D; Department of Neurology, Szent-Györgyi Albert Clinical Centre, Szent-Györgyi Albert Faculty of Medicine, University of Szeged, Szeged., Gárdián G; Department of Neurology, Szent-Györgyi Albert Clinical Centre, Szent-Györgyi Albert Faculty of Medicine, University of Szeged, Szeged., Szpisjak L; Department of Neurology, Szent-Györgyi Albert Clinical Centre, Szent-Györgyi Albert Faculty of Medicine, University of Szeged, Szeged., Salamon A; Department of Neurology, Szent-Györgyi Albert Clinical Centre, Szent-Györgyi Albert Faculty of Medicine, University of Szeged, Szeged., Klivényi P; Department of Neurology, Szent-Györgyi Albert Clinical Centre, Szent-Györgyi Albert Faculty of Medicine, University of Szeged, Szeged., Zádori D; Department of Neurology, Szent-Györgyi Albert Clinical Centre, Szent-Györgyi Albert Faculty of Medicine, University of Szeged, Szeged.

Publikováno v: Ideggyogyaszati szemle [Ideggyogy Sz] 2023 Jan 30; Vol. 76 (1-2), pp. 37-45.

Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.

Autor: Müller M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Posch F; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Kiem D; IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria., Barth D; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Horvath L; Department of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria., Stotz M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Schaberl-Moser R; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Pichler M; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Greil R; IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria., Jost PJ; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Seeber A; Department of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria., Amann A; Department of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria., Schlick K; IIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria., Gerger A; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Riedl JM; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, Graz 8036, Austria.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2021 Sep 30; Vol. 13, pp. 17588359211039930. Date of Electronic Publication: 2021 Sep 30 (Print Publication: 2021).

Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy.

Autor: Kiem D; Oncologic Center, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, 5020 Salzburg, Austria.; Cancer Cluster Salzburg, 5020 Salzburg, Austria., Leisch M; Oncologic Center, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, 5020 Salzburg, Austria.; Cancer Cluster Salzburg, 5020 Salzburg, Austria.; Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg Cancer Research Institute, 5020 Salzburg, Austria., Neureiter D; Cancer Cluster Salzburg, 5020 Salzburg, Austria.; Institute of Pathology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria., Haslauer T; Oncologic Center, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, 5020 Salzburg, Austria.; Cancer Cluster Salzburg, 5020 Salzburg, Austria.; Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg Cancer Research Institute, 5020 Salzburg, Austria., Egle A; Oncologic Center, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, 5020 Salzburg, Austria.; Cancer Cluster Salzburg, 5020 Salzburg, Austria.; Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg Cancer Research Institute, 5020 Salzburg, Austria., Melchardt T; Oncologic Center, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, 5020 Salzburg, Austria.; Cancer Cluster Salzburg, 5020 Salzburg, Austria.; Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg Cancer Research Institute, 5020 Salzburg, Austria., Topp MS; Medical Clinic and Polyclinic II, University Hospital Würzburg, 97080 Würzburg, Germany., Greil R; Oncologic Center, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, 5020 Salzburg, Austria.; Cancer Cluster Salzburg, 5020 Salzburg, Austria.; Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg Cancer Research Institute, 5020 Salzburg, Austria.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2021 May 21; Vol. 22 (11). Date of Electronic Publication: 2021 May 21.

Clinical Evidence of Methods and Timing of Proper Follow-Up for Head and Neck Cancers.

Autor: Gili, Riccardo^1,2 (AUTHOR) giliriccardo.rg@gmail.com, Caprioli, Simone^1,3 (AUTHOR) gianluca.sacco94@gmail.com, Lovino Camerino, Paola^4,5 (AUTHOR) lovino.pa@gmail.com, Sacco, Gianluca^1,2 (AUTHOR) tommirue@gmail.com, Ruelle, Tommaso^1,2 (AUTHOR) lucia.delmastro@unige.it, Filippini, Daria Maria^6,7 (AUTHOR) d.m.filippini@gmail.com, Pamparino, Silvia^3,8 (AUTHOR) giuseppe.cittadini@hsanmartino.it, Vecchio, Stefania² (AUTHOR), Marchi, Filippo^4,5 (AUTHOR) filippomarchi@hotmail.it, Del Mastro, Lucia^1,9 (AUTHOR), Cittadini, Giuseppe³ (AUTHOR)

Publikováno v: Onco. Dec2024, Vol. 4 Issue 4, p275-286. 12p.